Skip to main content
OpenTrials
Completed

NCT Number: NCT03282019

Study of Long-term HFNC for COPD Patients with HOT

This is a prospective, randomized parallel study for evaluation of the efficacy and safety of long-term nocturnal high-flow nasal cannula therapy (HFNC: with the myAIRVO2 as HFNC in this study) in stable COPD patients with the global initiative for chronic obstructive lung disease (GOLD) stage 2-4, PaCO2 >= 45 Torr and hypercapnia who require home oxygen therapy (HOT) using COPD exacerbation (Moderate or Severe).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease (COPD) Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kobe City Medical Center General Hospital

Kobe, Hyōgo, 6500047, Japan

About this study

An abroad study of the stable COPD patients was reported that HFNC usage decreased the frequency of COPD exacerbation.

In addition, the result of the pilot study (NCT02545855) of the stable COPD patient in Japan is indicated that HOT with HFNC improved their QOL and PaCO2 by comparing to HOT only.

Therefore, this study is planned to indicate the efficacy of HFNC which can increase the ventilation efficiency and have the function of heated humidification, by comparing HOT with HFNC to HOT only.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are diagnosed with the global initiative on obstructive lung disease (GOLD) stage 2-4 COPD.
  • Patients who have received nocturnal HOT 16 hours or more per day for 1 month or more at the time of the informed consent.
  • Patients with PaCO2 >= 45 Torr and pH >= 7.35 at screening.
  • Patients with COPD exacerbation (Moderate or Severe; judged by the investigators) within the past 1 year prior to the informed consent.
  • Patients who are more than 40 years old at the time of the informed consent.
  • Patients who agree to participate in the study with the written informed consent.

Exclusion criteria

  • Patients with severe kidney, liver or cardiovascular disease.
  • Patients with active malignant tumor.
  • Patients with acute disease.
  • Patients who are diagnosed with asthma. (Excluding COPD patients with history of asthma).
  • Patients who have any history of obstructive sleep apnea syndrome (OSAS) or are highly-suspected cases in the clinical. (Excluding patients who are denied the diagnosis of OSAS by the result of overnight polysomnography.)
  • Patients with diseases that affecting the efficacy endpoints (for example: active pulmonary infection, clinically significant pulmonary fibrosis and bronchiectasis, α-1-antitrypsin deficiency etc.,) and are regarded as inadequate for the study by the investigators.
  • Patients who have experienced a COPD exacerbation (any Severity: judged by the investigators) within the past 4 weeks prior to the informed consent.
  • Patients who are receiving nocturnal noninvasive positive pressure ventilation (NPPV), or who had been received it within 4 weeks prior to the informed consent.
  • Patients who have used HFNC at home within the past 1 year prior to the informed consent, or are using any HFNC. (Excluding patients who used HFNC during hospitalization due to acute respiratory failure within 1 year prior to the informed consent.)
  • Patients with history of tracheotomy, severe pharyngeal surgery or severe nasal cavity surgery within the past 6 months prior to the informed consent.
  • Patients who are pregnant.
  • Patients with cognitive impairment or mental disorder who are regarded as inadequate to evaluate for the study by the investigators.
  • Patients who are regarded as being unable to operate the myAIRVO2 adequately at home by the investigators.
  • Patients who have participated in the other study at the time of the informed consent, or will participate in the other study.
  • Any other cases who are regarded as inadequate for the study enrollment by the investigators.

Treatment and study plan

High-flow nasal cannula therapy

Device

Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.

Other names: myAIRVO2®

Home oxygen therapy (HOT)

Device

All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.

Primary outcomes

  1. Frequency (the number of occurrences per year) of COPD exacerbation (Moderate or Severe)

    Time frame: 52weeks

    COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.

Secondary outcomes

  1. Term from enrollment to the date of first COPD exacerbation (Moderate or Severe)

    Time frame: up to 52 weeks

    The term from enrollment to the date of first COPD exacerbation is a duration from the start of intervention (Week0) to the date of first COPD exacerbation or death from any cause which ever comes first.

    The date of first COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.

  2. Term from enrollment to death from any cause

    Time frame: up to 52 weeks

    Term from enrollment to death from any cause is a duration from the start of intervention (Week0) to death from any cause.

  3. Frequency (the number of occurrences per year) of COPD exacerbation (All Severity and Severe only)

    Time frame: 52weeks

    COPD exacerbation will be assessed by the disease diary which is kept by each patient within the term of intervention.

  4. Total St. George's respiratory questionnaire (SGRQ-C) score, and each components score (symptom score, activity score, and impact score)

    Time frame: at 0, 12, 24 and 52 weeks

    SGRQ-C score will be assessed by Japanese version of the SGRQ-C value sets including each components score (symptom score, activity score, and impact score).

  5. Quality-adjusted life year (QALY) by mapping the EQ-5D-5L utility scores

    Time frame: at 0, 12, 24 and 52 weeks

    Quality-adjusted life year (QALY) of the subjects will be assessed by Japanese version of the EQ-5D-5L value sets including assessment of changes from baseline in the EQ-5D-5L utility index scores and visual analogue scale scores.

  6. Total SRI (Severe Respiratory Insufficiency Questionnaire) score

    Time frame: at 0, 12, 24 and 52 weeks

    Total SRI score will be assessed by Japanese version of the SRI value sets.

  7. Total PSQI-J(Japanese version of the Pittsburgh Sleep Quality Index) score

    Time frame: at 0, 12, 24 and 52 weeks

    Total PSQI-J score will be assessed by Japanese version of the PSQI value sets.

  8. Dyspnea intensity: the modified medical research council (mMRC) score

    Time frame: 52weeks

    Dyspnea intensity will be evaluated by the modified medical research council (mMRC) score.

  9. Arterial blood gas analysis (ABG): pH, PaO2, PaCO2, HCO3-, BE

    Time frame: 52weeks

    ABG will be evaluated by the blood gas analysis equipment.

  10. Oxygen Saturation (SpO2)

    Time frame: 52weeks

    SpO2 will be evaluated by Pulse Oximeter.

  11. Pulmonary functions: FVC, FEV1, FEV1%

    Time frame: 52weeks

    Lung function of the subjects will be assessed by the pulmonary function tests in the following indicators: vital capacity (VC, %VC), forced vital capacity (FVC, %FVC), forced expiratory volume in 1 second (FEV1, ％FEV1), FEV1/FVC.

  12. 6-minute walk test (6MWT)

    Time frame: at 0, 12, 24 and 52 weeks

    6MWT for the respiration rehabilitation is defined as the functional exercise capacity which is assessed by the following indicators: the distance (m), changes in pre- and post-6MWT pulse oximeter (SpO2), and post-6MWT modified borg scale.

  13. Term from enrollment to the date of long-term (more than 1month) NPPV(Noninvasive Positive Pressure Ventilation) usage

    Time frame: 52weeks

    The term from the start of intervention (Week0) to the date of Long-term NPPV usage.

    Long-term NPPV usage is defined as more than 1month NPPV usage.

  14. Flow rate(Oxygen / Total) (Arm A only)

    Time frame: 52weeks

    Oxygen flow rate / Total flow rate will be confirmed by the record of numerical value displayed on the device.

  15. Total hours of myAIRVO2-use (Arm A only)

    Time frame: 52weeks

    Total hours of myAIRVO2-use will be confirmed by the record of numerical value displayed on the device.

  16. Adverse events

    Time frame: 52weeks

    Adverse events will be determined by the latest version of MedDRA/J （Medical Dictionary for Regulatory Activities/J）at the time of Database lock.

Other outcomes

  1. Correlation between frequency of COPD exacerbation (All Severity and Severe only) and amount of ABG change

    Time frame: 52weeks

    Amount of ABG change will be calculated by the ABG value at before and after the intervention.

  2. Correlation between frequency of COPD exacerbation (All Severity and Severe only) and amount of SpO2 change

    Time frame: 52weeks

    Amount of SpO2 change will be calculated by the ABG value of before and after the intervention.

Sponsors and collaborators

Lead sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Other

Collaborators

  • Kobe City Medical Center General Hospital

Registry information

Official study title

Efficacy and Safety of Long-term High-flow Nasal Cannula Oxygen Therapy in Stable COPD Patients with Home Oxygen Therapy (HOT): a Multicenter, Prospective, Randomized Controlled Study

Acronym: FLOCOP

Important dates

Study start
2017
Primary completion
2020
Study completion
2020
First posted
Sep 13, 2017
Registry last updated
Nov 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.